2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...
Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
Zacks.com on MSN3d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...
Health-care companies declined as concerns about AbbVie and Humana weighed. Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage trials ...
4don MSN
Gain insight on Rigel Pharmaceuticals, AbbVie and more in the latest Market Talks covering the Health Care sector.
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
AbbVie shares, which hit a 52-week high in late October after the drugmaker posted quarterly earnings that topped Wall Street's expectations and raised its dividend by nearly 6%, were recently down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback